Tweenvest Stocks

Nasus Pharma Ltd. (NYSEAM: NSRX)

Health Care · Pharmaceuticals · IL

$4.04

+11.60% today · -57.9% 1Y

Nasus Pharma Ltd. (NYSEAM: NSRX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $42.39M and employs 7 people.

Over the last twelve months the share price has lost 57.9%, trading between 1.98 and 9.99.

Tweenvest scores Nasus Pharma Ltd. across four factors: quality 26/100. Its strongest factor is quality.

NSRX price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$42.39M
Revenue (TTM)
P/E
EPS
-0.73
Dividend yield
Beta (5Y)
52-week high
$9.99
52-week low
$1.98
Avg volume (3M)
Shares outstanding
11.71M
Employees
7
Next earnings

About Nasus Pharma Ltd.

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

ISIN
IL0012181553
Founded
2019
Listed since
Aug 13, 2025
Exchange
NYSE American LLC
Currency
USD
CompanyMarket capPriceDay
Eli Lilly and CompanyNYSE: LLY$1.12T$1,243.40-0.96%
Johnson & JohnsonNYSE: JNJ$651.25B$273.46+1.19%
Merck & Co., Inc.NYSE: MRK$376.37B$150.49-1.35%
Roche Holding AGSWX: ROP$373.91BCHF370.40-1.38%
Novartis AGSWX: NOVN$302.17BCHF127.42+0.85%
AstraZeneca PLCLSE: AZN$258.76B£121.10-1.06%
Novo Nordisk A/SCPSE: NOVO B$207.84BDkr300.85+1.59%
Pfizer Inc.NYSE: PFE$159.99B$27.98-0.32%

Browse every Pharmaceuticals company →

Figures last refreshed Aug 18, 2026.